{"id":"sh-1028-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Unknown"}]},"_chembl":{"chemblId":"CHEMBL5960902","moleculeType":null,"molecularWeight":"472.64"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"SH-1028 tablets work by binding to the molecular target, which results in the desired therapeutic effect.","oneSentence":"SH-1028 tablets are a small molecule drug that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:34:14.528Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Unknown"}]},"trialDetails":[{"nctId":"NCT06080776","phase":"PHASE3","title":"SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations","status":"RECRUITING","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2023-05-11","conditions":"Non-small Cell Lung Cancer","enrollment":242},{"nctId":"NCT04808648","phase":"PHASE1","title":"The Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SH-1028","status":"UNKNOWN","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2021-04-06","conditions":"Healthy Male Volunteers","enrollment":40},{"nctId":"NCT04239833","phase":"PHASE3","title":"A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2020-01-31","conditions":"Non-Small Cell Lung Cancer","enrollment":240},{"nctId":"NCT03973632","phase":"PHASE1","title":"Pharmacokinetic Study of SH-1028 Tablets in Healthy Subjects Under Fasting and Fed Conditions","status":"UNKNOWN","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2019-07","conditions":"Healthy Volunteer","enrollment":16},{"nctId":"NCT03618043","phase":"PHASE1","title":"Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer","status":"UNKNOWN","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2018-09-13","conditions":"Advanced Solid Cancer","enrollment":14},{"nctId":"NCT03603262","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of SH-1028 in Patients With Advanced NSCLC","status":"UNKNOWN","sponsor":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","startDate":"2018-04-25","conditions":"Non-small Cell Lung Cancer","enrollment":85}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SH-1028 tablets","genericName":"SH-1028 tablets","companyName":"Nanjing Sanhome Pharmaceutical, Co., Ltd.","companyId":"nanjing-sanhome-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SH-1028 tablets are a small molecule drug that targets the molecular target. Used for Unknown.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}